Table of contents
International Treaty Constraints (and How Countries Navigate Them)
Constraints, flexibility, and legal workarounds.
Executive Summary
By this point in the series, the domestic case has already been made.
We have already covered why prohibition underperforms, why risk-based drug regulation is more honest than one-size-fits-all law, why the highest-risk lane belongs in a regulated pharmacy model, why treatment on demand matters, why public safety enforcement should focus on real harms, and how reform can move through federal, state, and local pathways.
So Part 35 answers the next obvious question:
What about the international rules?
That question matters because the three core UN drug conventions are real legal constraints, not just talking points. The Single Convention on Narcotic Drugs requires parties, subject to the Convention, to limit the production, manufacture, export, import, distribution, trade, use, and possession of controlled drugs exclusively to medical and scientific purposes.[1] The 1971 Convention on Psychotropic Substances applies a similar medical-and-scientific rule to substances in Schedules II, III, and IV.[2] And the 1988 Convention says that, subject to constitutional principles and the basic concepts of a state’s legal system, parties must criminalize possession, purchase, or cultivation of narcotic drugs or psychotropic substances for personal consumption contrary to the earlier conventions.[3]
That sounds rigid, and in some ways it is.
But the story is not just “treaties forbid everything.” It is more complicated and more useful than that.
INCB has said clearly that non-medical cannabis legalization contravenes the 1961 treaty, but it has also said the convention-based system offers significant treaty flexibility through decriminalization and depenalization to protect public health, avoid unnecessary incarceration, and address illicit markets.[4] Portugal used that flexibility through decriminalization. Bolivia used denunciation and re-accession with a reservation on coca leaf practices, the Bolivia coca reservation. Canada chose a broad adult-use model even though INCB called it incompatible with cannabis treaty obligations. Germany, Malta, and Luxembourg moved through narrower, non-commercial, or experimental pathways that appear designed to stay closer to the treaties, even though they still live in a contested zone where cannabis treaty obligations remain unresolved.[4][5][6][7][8][9][10][11]
That is the real point of this chapter.
International drug treaties constrain reform, but they do not freeze it.
Cannabis treaty obligations are real, but they do not make every reform path identical.
The UN drug conventions contain more room for health-first and non-carceral approaches than many people admit.
And drug treaty reform does not always mean one giant diplomatic revolution before anything practical can happen.
The Treaty Problem This Chapter Solves
A lot of people talk about international law in one of two lazy ways.
The first lazy version says the treaties make reform impossible, so there is no point planning anything serious.
The second lazy version says the treaties do not matter, so policymakers should ignore them and improvise.
Both are wrong.
The truth is harder.
International drug treaties matter because they still shape how governments defend, limit, or justify reform. But those same UN drug conventions also leave different kinds of room for different kinds of change. Some reforms fit more comfortably inside the treaty system. Some push against the outer edge of cannabis treaty obligations. Some amount to open non-compliance dressed in political necessity. Some involve formal workarounds. That is what this chapter is for: separating the legally easier paths from the legally harder ones and showing how countries actually navigate them.[1][2][3][4]
1. What International Drug Treaties Actually Require
The starting point has to be the texts themselves.
The Single Convention on Narcotic Drugs is still the backbone of the treaty system. Article 4 says parties must take legislative and administrative measures, subject to the Convention, to limit the production, manufacture, export, import, distribution, trade in, use, and possession of drugs exclusively to medical and scientific purposes.[1] The 1971 Convention on Psychotropic Substances uses the same basic logic for the psychotropic schedules it covers, limiting manufacture, export, import, distribution, stocks, trade, use, and possession to medical and scientific purposes.[2]
The 1988 Convention is where personal possession becomes more legally charged. Article 3(2) says that, subject to constitutional principles and the basic concepts of the domestic legal system, each party must adopt measures necessary to establish as a criminal offence the possession, purchase, or cultivation of narcotic drugs or psychotropic substances for personal consumption contrary to the 1961 and 1971 conventions.[3] That language matters because it creates pressure toward criminalization while also explicitly acknowledging domestic constitutional limits.[3]
This is the first big takeaway for the whole series:
• the Single Convention on Narcotic Drugs is stricter than many reformers like to admit
• the 1988 Convention is more flexible than many prohibitionists like to admit
• the UN drug conventions do not treat adult-use legalization, medical access, decriminalization, and public-health diversion as the same thing
That is exactly why the phrase cannabis treaty obligations matters. The treaties do not create one uniform answer for all reform. They create different levels of friction depending on what kind of reform a government is trying to build.
2. Where the UN Drug Conventions Leave Treaty Flexibility
This is the part people often skip.
The treaties are restrictive, but they are not monolithic.
INCB’s 2023 statement on cannabis says plainly that non-medical legalization contravenes the 1961 Convention. But in the same statement, INCB also says governments looking for alternatives regarding cannabis offences should remember that the conventions offer significant treaty flexibility, including decriminalization and depenalization, to protect young people, improve public health, avoid unnecessary incarceration, and address illicit markets and related crime.[4]
That is a huge point.
It means the legal gap between “criminal prohibition forever” and “fully commercial adult-use market” is wider than a lot of people assume.
Portugal is the clearest example of that middle ground. SICAD’s official English-language decriminalization brochure says Law 30/2000 keeps drug use and possession prohibited, but possession up to a 10-day personal-use threshold is no longer a crime. Users are not brought to court, do not incur prison sentences, and do not get criminal records, though they may face administrative sanctions through the Commissions for the Dissuasion of Drug Addiction.[5] SICAD also says the Portuguese model privileges health and social intervention rather than criminal process.[5]
That is why decriminalization remains one of the strongest examples of drug treaty reform that fits inside existing UN drug conventions more comfortably than full adult-use legalization does.
It also matters for the rest of this series because the treaty flexibility space lines up well with many of the arguments already made here:
• reduce incarceration without pretending drugs are harmless
• strengthen treatment on demand
• preserve public safety enforcement against trafficking and violence
• move toward a more serious risk-based drug regulation model over time
• use health and administrative responses where criminal law is not buying better outcomes
That is what real treaty flexibility looks like.
3. Cannabis Treaty Obligations and the Open-Breach Path: Canada and Uruguay
The next category is the bluntest one.
Some countries do not try to fit their non-medical cannabis model neatly inside the treaties. They move anyway.
Canada is the cleanest example.
Canada’s Cannabis Act states its purpose clearly: protect public health and public safety, protect young persons, provide for licit production to reduce illicit activities, deter illicit activities through enforcement, and reduce the burden on the criminal justice system.[7] Those are familiar goals to anyone who has read this series. They are also exactly the kinds of goals people cite when making the domestic case for drug regulation.
But legally, Canada did not pretend this was treaty-comfortable. INCB said in 2018 that Canada’s legalization of cannabis for non-medical purposes was incompatible with Canada’s international obligations and violated the 1961 treaty’s fundamental requirement that controlled drugs be limited to medical and scientific purposes.[6] INCB’s 2023 statement made the same broader point, saying non-medical cannabis legalization contravenes the 1961 Convention and noting that illegal cannabis supply remained significant in both Canada and Uruguay.[4]
That matters because it shows one real pathway for drug treaty reform:
move first, accept the legal conflict, and defend the policy politically rather than doctrinally.
That is a real path. It is also the legally roughest path.
Uruguay sits in a similar category. INCB’s 2023 statement grouped legalizing jurisdictions together and said illicit markets persisted at high levels, reaching nearly 50 per cent in Uruguay and around 40 per cent in Canada.[4] The broader lesson is not that legalization “failed.” It is that broad adult-use systems do not make black market drugs vanish automatically, and they do not erase cannabis treaty obligations just because domestic lawmakers say otherwise.[4]
This is why Part 29 mattered so much. Legal supply can shrink illicit markets, but only if the legal side is safer, visible, and competitive enough to pull buyers over. Treaties do not change that market reality.
4. Drug Treaty Reform by Reservation: Bolivia Coca Reservation
If Canada shows the open-conflict path, Bolivia shows the formal workaround path.
Bolivia’s approach matters because it is one of the clearest examples of a country using treaty law itself to reshape its obligations.
The UN Treaty Collection says Bolivia denounced the 1961 treaty in 2011, the denunciation took effect on 1 January 2012, and Bolivia later re-acceded with a reservation.[8] The reservation text says Bolivia reserves the right to allow traditional coca leaf chewing, the consumption and use of coca leaf in its natural state for cultural and medicinal purposes such as infusions, and the cultivation, trade, and possession of coca leaf to the extent necessary for those licit purposes.[8]
That is the Bolivia coca reservation in plain English.
It did not pretend the treaty meant something it obviously did not mean.
It did not simply ignore the treaty text.
It used a formal legal route to carve out a narrower national position.
That matters because drug treaty reform is not always just about broad political defiance. Sometimes it is about using denunciation, re-accession, and reservation strategy to align treaty obligations with domestic constitutional and cultural commitments.
At the same time, the Bolivia coca reservation is not a universal cheat code. It addressed a historically and culturally specific issue tied to coca leaf, not a general adult-use cannabis market. So it is a real precedent for formal legal workarounds, but not a one-size-fits-all answer for cannabis treaty obligations.
Still, it proves something important:
International drug treaties do not remove all formal legal agency from states.
5. Limited-Model Navigation: Germany, Malta, and Luxembourg
The next category is more subtle.
Instead of building a broad commercial market like Canada, some governments have moved through narrower, more controlled, or more experimental models.
Germany’s 2024 CanG is one example. Germany’s Federal Ministry of Health says the Cannabis Act legalized private home cultivation for adult personal use and legalized non-commercial collective cultivation in cannabis associations, while also regulating medical cannabis.[9] The ministry’s explanation emphasizes youth protection and a controlled approach rather than a full commercial retail market.[9]
Malta took a similar narrower path. The Maltese government said its 2021 law created the Authority on the Responsible Use of Cannabis, curbed illegal trafficking, created a regulatory framework to protect minors and society at large, allowed home cultivation up to four plants, and provided for strictly regulated outlets operated by non-profit associations.[10]
Luxembourg has also framed its pathway as staged and experimental. The Luxembourg government said residents would be allowed to cultivate up to four cannabis plants at home and, in a future experimental system of legal access for non-medical purposes, to buy cannabis in state points of sale. The government said the approach was grounded in public health, designed to reduce the illicit market, and meant to strengthen protection for vulnerable people, especially young people.[11]
These models matter because they show a third strategy for navigating cannabis treaty obligations:
build a narrower adult-use system that is harder to mistake for a normal commercial market.
That does not make the treaty question disappear. INCB’s general position remains that non-medical cannabis legalization contravenes the 1961 Convention.[4] So these limited models still live in a contested zone. But politically and legally they are different from saying, “Here is a national commercial market with ordinary branding and consumer promotion.”
That distinction fits naturally with the larger architecture of this series.
A narrow, non-commercial, controlled, health-justified model is closer in spirit to risk-based drug regulation than to laissez-faire legalization. It also fits better with the youth-protection, public safety, and accountability arguments made in Part 26, Part 27, and Part 28.
6. What International Drug Treaties Mean for U.S. Strategy
So what does all this mean for the United States?
It means the United States has options, but it needs to stop pretending all options are identical.
The easiest reforms to defend under the UN drug conventions are not broad non-medical cannabis commercialization. They are:
• decriminalization or depenalization of some possession offences
• stronger medical and scientific pathways
• improved treatment on demand
• tighter health-centered monitoring and privacy through 42 CFR Part 2
• more serious overdose prevention and medication access
• narrower high-risk medical lanes that look more like a regulated pharmacy model than ordinary consumer retail
Those paths fit better with existing treaty flexibility than a full commercial adult-use model does.[4][5]
That does not mean the U.S. cannot choose a broader path. It means policymakers should be honest about what they are doing.
If they move beyond what the treaties comfortably allow, that is not automatically disqualifying. Canada already shows that a state can do it. But it does change the legal and diplomatic posture. It turns reform from a question of “What does the treaty already permit?” into a question of “What kind of drug treaty reform or treaty tension are we willing to own openly?”
That honesty matters.
It matters for courts.
It matters for international diplomacy.
It matters for state and federal coordination.
And it matters for public trust.
The broader lesson is the same one this series keeps returning to:
The path forward is not one-size-fits-all.
A serious U.S. strategy should probably combine:
the federal and state pathway work from Part 31
the market and black market drugs logic from Part 29
the privacy and measurement rules from Part 30
the higher-duty lane from the regulated pharmacy model in Part 14
the public-health and buy-in logic from Parts 18 and 22
and a realistic map of which reforms sit inside treaty space, which press on treaty space, and which openly go beyond it
That is how you turn international drug treaties from a conversation-stopper into a planning problem.
The Bottom Line
The mistake is not taking the treaties seriously.
The mistake is treating them like a single unbreakable wall.
International drug treaties do constrain reform.
Cannabis treaty obligations are real.
The UN drug conventions still say controlled drugs should be limited to medical and scientific purposes, and the Single Convention on Narcotic Drugs still anchors that system.[1][2][3]
But the treaties also leave more room than the loudest prohibition voices admit.
There is treaty flexibility for decriminalization and depenalization.[4][5] There are formal legal workarounds like the Bolivia coca reservation.[8] There are narrow, non-commercial, and experimental models like those in Germany, Malta, and Luxembourg that try to navigate cannabis treaty obligations differently from Canada’s broad adult-use framework.[9][10][11] And there is still a live question of broader drug treaty reform if more countries decide that the treaty system no longer reflects the realities they are governing.
That is the practical takeaway for the rest of this series:
The treaties matter.
They do not decide everything.
And pretending they do is just another way of not doing the work.
Frequently Asked Questions
Do international drug treaties make reform impossible?
No. International drug treaties create real legal constraints, but they do not make every reform path impossible. The key is distinguishing reforms that fit inside treaty flexibility from reforms that openly conflict with treaty text.[1][2][3][4]
What are cannabis treaty obligations in plain English?
Cannabis treaty obligations come mainly from the Single Convention on Narcotic Drugs, which requires parties to limit production, distribution, trade, use, and possession of controlled drugs to medical and scientific purposes.[1] INCB has repeatedly said that non-medical cannabis legalization contravenes that rule.[4][6]
Are decriminalization and depenalization allowed under the UN drug conventions?
They appear to sit on firmer legal ground than full adult-use legalization. INCB says the conventions offer significant flexibility and specifically points to decriminalization and depenalization as alternative routes for handling cannabis offences.[4] Portugal’s official decriminalization model shows what that can look like in practice.[5]
What is the Bolivia coca reservation and why does it matter?
The Bolivia coca reservation matters because it shows a formal treaty-law workaround. Bolivia denounced the 1961 treaty, then re-acceded with a reservation allowing traditional coca leaf chewing and related cultural and medicinal uses.[8]
Are Germany, Malta, and Luxembourg treaty-compliant?
That is the contested part. Their narrower, non-commercial, or experimental models appear designed to stay closer to treaty limits than a broad commercial system, but INCB’s general view remains that non-medical cannabis legalization contravenes the 1961 Convention.[4][9][10][11] That makes these models legally narrower, but not necessarily free of treaty tension.
What is the most realistic U.S. path under existing law?
The most realistic path is probably layered: federal scheduling and privacy reform, state decriminalization and treatment financing, local implementation, and tighter high-risk medical lanes through risk-based drug regulation, a regulated pharmacy model, and treatment on demand. That stays closer to treaty flexibility than broad adult-use commercialization while still moving reform forward.
References
[1] International Narcotics Control Board. Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol. https://www.incb.org/incb/uploads/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf
[2] International Narcotics Control Board. Convention on Psychotropic Substances, 1971. https://www.incb.org/incb/uploads/documents/Psychotropics/conventions/convention_1971_en.pdf
[3] United Nations Office on Drugs and Crime. United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988. https://www.unodc.org/pdf/convention_1988_en.pdf
[4] International Narcotics Control Board. International Narcotics Control Board expresses concern over the trend to legalize non-medical use of cannabis, which contravenes the 1961 Single Convention on Narcotic Drugs. https://www.incb.org/incb/en/news/press-releases/2023/international-narcotics-control-board-expresses-concern-over-the-trend-to-legalize-non-medical-use-of-cannabis—which-contravenes-the-1961-single-convention-on-narcotic-drugs.html
[5] Serviço de Intervenção nos Comportamentos Aditivos e nas Dependências (SICAD). Decriminalisation Law. https://sicad.pt/BK/Publicacoes/Lists/SICAD_PUBLICACOES/Attachments/94/DesdobravelDescriminalizacao_PT_EN.pdf
[6] International Narcotics Control Board. Statement by the International Narcotics Control Board on the entry into force of Bill C-45 legalising cannabis for non-medical purposes in Canada. https://www.incb.org/incb/en/news/press-releases/2018/statement-by-the-international-narcotics-control-board-on-the-entry-into-force-of-bill-c-45-legalising-cannabis-for-non-medical-purposes-in-canada.html
[7] Department of Justice Canada. Cannabis Act. https://laws-lois.justice.gc.ca/eng/acts/C-24.5/
[8] United Nations Treaty Collection. Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol, Bolivia reservation and re-accession status. https://treaties.un.org/Pages/ViewDetails.aspx?chapter=6&mtdsg_no=VI-18&src=TREATY
[9] German Federal Ministry of Health. Cannabisgesetz (CanG). https://www.bundesgesundheitsministerium.de/service/gesetze-und-verordnungen/detail/cannabisgesetz
[10] Government of Malta. New law on the responsible use of cannabis enters into force. https://www.gov.mt/en/Government/DOI/Press%20Releases/Pages/2021/December/18/pr212248en.aspx
[11] Government of Luxembourg. Presentation of the experimental scheme for legal access to cannabis for non-medical purposes. https://gouvernement.lu/fr/actualites/toutes_actualites/communiques/2023/04-avril/28-dispositif-experimental-cannabis.html
If you want to follow the full series as it publishes, visit the full Drug Legalization Series. If you prefer audio conversations on recovery, reentry, and purpose, check the podcast page. For program directors building reentry and transition programming, see ReturnPath reentry curriculum. For the personal story behind this work, read A Vision of Hope. To invite Andrew for a keynote or panel, see speaking.